Clinical Trial Update: A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer [Phase 1]

View source ↗

Summary

Chiome Bioscience's CBA-1205, an anti-DLK1 monoclonal antibody, is in a Phase I first-in-human trial for advanced solid tumors including hepatocellular carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Malignant Melanoma

Drugs mentioned

• CBA-1205 (anti-DLK1 monoclonal antibody)

Snippet

Sponsor: Chiome Bioscience Inc. | Conditions: Solid Tumors, Hepatocellular Carcinoma (HCC) | Phase 1 | Status: RECRUITING